Acute Myeloid Leukemia
Conditions
Keywords
leukemia, myeloid leukemia
Brief summary
This study is to determine the safety and recommended dosing of Minnelide in Acute Myeloid Leukemia (AML)
Detailed description
This phase 1 dose escalation clinical trial will establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of Minnelide as single-agent in relapsed/refractory (R/R) acute myeloid leukemia (AML) patients who are ineligible to receive intensive chemotherapy. The oral formulation of Minnelide will be used. Minnelide is a prodrug of triptolide (a potent heat shock protein (HSP) 70 inhibitor) with promising preclinical activity in AML.
Interventions
DRUGMinnelide
Patients will take Minnelide orally once daily on Days 1-21 of 28 day Cycle. Dose Escalation Schedule: Dose Level -1: .5 mg, Dose Level 1: .75 mg, Dose Level 2: 1 mg, Dose Level 3: 1.25 mg.
Sponsors
Minneamrita Therapeutics LLC
H. Lee Moffitt Cancer Center and Research Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults ages 18 years or older. * Participant must have relapsed or refractory acute myeloid leukemia (AML) (excluding acute promyelocytic leukemia). * Relapsed patients must have received at least 1 induction chemotherapy regimen or two cycles of a hypomethylating agent and achieved a Complete Response (CR), followed by relapse of disease. * Refractory patients must have received at least 1 induction chemotherapy regimen or two cycles of hypomethylating agent without achieving a CR. * Eastern Cooperative Oncology Group (ECOG) performance status \<2. * Participants must have acceptable organ function. * Be able and willing to adhere to the study visit schedule and other protocol requirements. * Must be able to swallow capsules and have no evidence of GI tract abnormality that would alter the absorption of oral medications. * The effects of Minnelide on the developing human fetus are unknown. For this reason, women of child-bearing potential must have a negative serum or urine pregnancy test within 24 hours prior to beginning study treatment. * Participants of childbearing potential must practice contraception. Females of childbearing potential: Recommendation is for 2 effective contraceptive methods during the study. Male participants with female partners who are of childbearing potential: Recommendation is for male and partner to use at least 2 effective contraceptive methods, as described above, during the study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with Minnelide, breastfeeding mothers must agree to discontinue nursing if the mother is treated with Minnelide. * Provision of signed and dated informed consent document * Patients with prior allogeneic stem cell transplant who experience relapse of AML are eligible if they are off of immunosuppressive therapy and without any evidence of graft-versus-host disease (GVHD)
Exclusion criteria
* Participants may not have received any therapy with any investigational products, systemic anti-neoplastic therapy, or radiotherapy within 14 days prior to Cycle 1 Day 1. Patients actively receiving hydroxyurea are eligible and may continue to receive hydroxyurea during protocol treatment. * Candidates for standard and/or potentially curative treatments. * Major surgery within 28 days prior to Cycle 1 Day 1. * New York Heart Association Class III or IV heart failure, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on an electrocardiogram (EKG) * Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy * Known, active HIV, Hepatitis A, B or C infection (prior Hepatitis C infection that has been treated and determined to be cured is allowed) * Symptomatic central nervous system (CNS) involvement with leukemia * A concurrent second active and non-stable malignancy with the exception of non-melanoma skin cancer or carcinoma in-situ.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Dose (MTD) of Minnelide | Up to 28 days for each dosing cohort | MTD will be determined by testing increasing doses up to 1.25 mg daily. MTD reflects highest dose of drug that did not cause a Dose Limiting Toxicity (DLT). |
| Number of Participants Who Experience Dose Limiting Toxicities (DLTs) | Up to 28 days for each dosing cohort | A DLT is any Grade 3 or 4 drug-related non-hematologic toxicity, with some exceptions per protocol. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete Response (CR) | Up to 12 months | Participants who experience Complete Response (CR) and Complete Response with Incomplete Blood Count Recovery (CRi) rate as defined by 2003 International Working Group (IWG) for AML. |
| Overall Response Rate (ORR) | Up to 12 months | Overall Response Rate is defined as CR + CRi + partial response (PR) as defined by 2003 IWG criteria for AML. |
| Relapse Free Survival (RFS) | Up to 18 months | RFS is defined as time interval between achievement of CR to time of relapse. |
| Overall Survival (OS) | Up to 12 months | OS defined as time interval from time of enrollment onto the clinical trial to death from any cause. |
Countries
United States
Outcome results
None listed